Current Development Status of MEK Inhibitors

The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclinical data and clinical study progress, has been summarized in this review. Different MEK inhibitors, possessing specific physicochemical properties and bioactivity characteristics, may pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Ying, Tian, Hongqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151813/
https://www.ncbi.nlm.nih.gov/pubmed/28954413
http://dx.doi.org/10.3390/molecules22101551
_version_ 1783357236986249216
author Cheng, Ying
Tian, Hongqi
author_facet Cheng, Ying
Tian, Hongqi
author_sort Cheng, Ying
collection PubMed
description The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclinical data and clinical study progress, has been summarized in this review. Different MEK inhibitors, possessing specific physicochemical properties and bioactivity characteristics, may provide different options for patients seeking treatment for cancer. Moreover, the combination of the MEK inhibitors with other therapies—such as chemotherapy, targeted therapy, and immunotherapy—may be a promising approach for clinical use.
format Online
Article
Text
id pubmed-6151813
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61518132018-11-13 Current Development Status of MEK Inhibitors Cheng, Ying Tian, Hongqi Molecules Review The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclinical data and clinical study progress, has been summarized in this review. Different MEK inhibitors, possessing specific physicochemical properties and bioactivity characteristics, may provide different options for patients seeking treatment for cancer. Moreover, the combination of the MEK inhibitors with other therapies—such as chemotherapy, targeted therapy, and immunotherapy—may be a promising approach for clinical use. MDPI 2017-09-26 /pmc/articles/PMC6151813/ /pubmed/28954413 http://dx.doi.org/10.3390/molecules22101551 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Cheng, Ying
Tian, Hongqi
Current Development Status of MEK Inhibitors
title Current Development Status of MEK Inhibitors
title_full Current Development Status of MEK Inhibitors
title_fullStr Current Development Status of MEK Inhibitors
title_full_unstemmed Current Development Status of MEK Inhibitors
title_short Current Development Status of MEK Inhibitors
title_sort current development status of mek inhibitors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151813/
https://www.ncbi.nlm.nih.gov/pubmed/28954413
http://dx.doi.org/10.3390/molecules22101551
work_keys_str_mv AT chengying currentdevelopmentstatusofmekinhibitors
AT tianhongqi currentdevelopmentstatusofmekinhibitors

Ejemplares similares